Playback speed
10 seconds
ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant Sacituzumab Govitecan + Pembro vs Pembro ± Capecitabine in TNBC and Residual Disease After Neoadjuvant Therapy and Surgery"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Sara Tolaney
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Sara Tolaney
0 views
June 7, 2023
Comments 0
Login to view comments.
Click here to Login